Barcelona, Spain – International research led by the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University, in collaboration with Hospital del Mar, Hospital Clínic, Charité – Medical University of Berlin, and the universities of Oslo and Genoa, has developed a computational biology tool, based on multi-level network...
Latest News
SOUTH SAN FRANCISCO, Calif. — Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, today announced updated efficacy and safety data from its Phase 2 clinical trial of picoplatin in patients with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The data demonstrate that picoplatin in combination with...
LONDON, UK – Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel...
INGELHEIM AM RHEIN, Germany – Boehringer Ingelheim today announced new data from the global Phase III FIBRONEER™ program on nerandomilast, an investigational oral preferential PDE4B inhibitor, which is currently not approved for use. The new pooled analyses, the first to demonstrate a nominally significant reduction in risk of death across...
SEOUL, South Korea – A research team at the Yonsei University College of Medicine reported in Seminars in Arthritis & Rheumatism that poor physical function at baseline is associated with premature death in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA)—2 conditions that fall under the umbrella of...
GAINESVILLE, Fla. — The idea that anti-inflammatory drugs might protect people struggling with dementia from Alzheimer’s disease has received a blow with the online release of a study of human brain tissue in Acta Neuropathologica. Researchers with the McKnight Brain Institute of the University of Florida, in collaboration with scientists...
Posaconazole was non-inferior to voriconazole for the primary treatment of invasive aspergillosis, according to an international, randomized, double-blind, double-dummy, controlled non-inferiority trial published in the Lancet. Between October 25, 2013, and September 10, 2019, investigators randomly assigned 585 participants to receive either posaconazole or voriconazole. In the posaconazole group, 288 participants...
SAN DIEGO, CA — Poseida Therapeutics, Inc., a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today highlighted recent progress across the company’s cell and gene therapy portfolio and provided updates on anticipated upcoming milestones. “In 2023, we made...
SAN DIEGO, Calif. — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced new data from a subset of patients in an ongoing Phase 1 study of its lead program, P-BCMA-ALLO1. Results...
MELBOURNE, Australia – Neuren Pharmaceuticals Limited (ASX: NEU) has received clear and constructive guidance from the FDA Office of Neuroscience in pre-IND meetings for Phase 2 clinical trials of NNZ-2591 in Phelan-McDermid, Angelman and Pitt Hopkins syndromes. All three syndromes are serious neurological disorders that emerge in early childhood and have no...